BTX - BioTime, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

BioTime, Inc.

1010 Atlantic Avenue
Suite 102
Alameda, CA 94501
United States
510-521-3390
http://www.biotimeinc.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees92

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael D. WestCo-CEO & Director758.57kN/A1953
Mr. Aditya P. MohantyCo-CEO, Pres & Director763.25kN/A1967
Mr. Russell L. SkibstedChief Financial Officer493.25kN/A1959
Mr. Dan L. LawrenceDirector of Investor Relations & Corp. CommunicationsN/AN/AN/A
Dr. Stephana E. Patton Ph.D., J.D.Gen. Counsel and Corp. Sec.N/AN/A1971
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Corporate Governance

BioTime, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.